Immunotherapy: a promising approach for glioma treatment

Feroza Yasinjan; Yang Xing; Huayue Geng; Rui Guo; Lei Yang; Ziling Liu; Hong Wang

doi:10.3389/fimmu.2023.1255611

Immunotherapy: a promising approach for glioma treatment

Front Immunol. 2023 Sep 7:14:1255611. doi: 10.3389/fimmu.2023.1255611. eCollection 2023.

Authors

Feroza Yasinjan¹, Yang Xing^{1

2}, Huayue Geng¹, Rui Guo³, Lei Yang¹, Ziling Liu¹, Hong Wang¹

Affiliations

¹ Cancer Center, The First Hospital of Jilin University, Changchun, China.
² Department of Neurosurgery, The First Hospital of Jilin University, Changchun, China.
³ Clinical Laboratory, The First Hospital of Jilin University, Jilin University, Changchun, China.

Abstract

Gliomas are the most prevalent primary malignant brain tumors worldwide, with glioblastoma (GBM) being the most common and aggressive type. Despite two decades of relentless pursuit in exploring novel therapeutic approaches for GBM, there is limited progress in improving patients' survival outcomes. Numerous obstacles impede the effective treatment of GBM, including the immunosuppressive tumor microenvironment (TME), the blood-brain barrier, and extensive heterogeneity. Despite these challenges, immunotherapies are emerging as a promising avenue that may offer new hope for the treatment of gliomas. There are four main types of immunotherapies for gliomas, immune checkpoint blockades, chimeric antigen receptor T-cell therapies, vaccines, and oncolytic viruses. In addition, gene therapy, bispecific antibody therapy, and combine therapy are also briefly introduced in this review. The significant role of TME in the process of immunotherapies has been emphasized in many studies. Although immunotherapy is a promising treatment for gliomas, enormous effort is required to overcome the existing barriers to its success. Owing to the rapid development and increasing attention paid to immunotherapies for gliomas, this article aims to review the recent advances in immunotherapies for gliomas.

Keywords: ICB; car-t; glioma; immunotherapy; oncolytic viruses; tumor microenvironment; vaccine.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Glioblastoma*
Glioma* / therapy
Humans
Immunotherapy
Immunotherapy, Adoptive
Radioimmunotherapy
Tumor Microenvironment

Grants and funding

This work was supported by Natural Science Foundation of China grants (81500116) to HW, Jilin Science and Technique development grants (20200201472JC) to HW, Jilin Science and Technique development grants (YDZJ202301ZYTS092) to RG, National College Students’ innovation and entrepreneurship training program (202210183300) to YX, and College Students’ innovation and entrepreneurship training program of Jilin University (X202210183572) to FY.